Exiqon today announced that it granted a non-exclusive license to Idexx Laboratories, Inc., to use Locked Nucleic Acid (LNA) technology in products for veterinary diagnostics. LNA provides unique characteristics to molecular assays and offers many possibilities for developing competitive products. Exiqon will receive upfront, milestones and royalty payments on global sales of the products covered by this agreement. Financial terms of the agreement were not disclosed. “We are pleased to see Idexx Laboratories has chosen to apply Exiqon's proprietary technology in the field of veterinary diagnostics,” says Lars Kongsbak, CEO and president of Exiqon. “We are excited that the LNA technology is now being applied in veterinary diagnostic products which emphasizes the broad applicability of the LNA technology.” <Home>
